OBJECTIVE—To determine whether patients developing ulcers had previously been identified as being at high risk of ulceration using the Scottish Care Information–Diabetes Collaboration (SCI-DC) ulcer risk score and whether the risk score predicts ulcer healing.

RESEARCH DESIGN AND METHODS—All patients attending the diabetes foot clinic with an ulcer had been assessed for foot ulcer risk using the SCI-DC risk calculator, which categorizes patients into low, moderate, or high risk of ulceration. Information on foot pulses, neuropathy, foot deformity, previous ulcer, ulcer site, depth, and presence of sepsis was recorded and related to ulcer outcome. Patients were followed up until outcome was achieved (median 3 months [range 1–33]).

RESULTS—Of patients attending the clinic with a foot ulcer (mean [±SD] age 67.3 ± 12.7 years, 68% male), 68% were previously recognized to be at high risk of foot ulceration, and 98% were high or moderate risk. Of 221 ulcers, the healing rate was 75% overall but was lower for high-risk patients compared with other patients (68 vs. 93%; P < 0.0001). Of the remainder, 3% became chronic ulcers, 12% required minor or major amputation, and 10% died with their ulcer. In multivariate analysis, absent pulses, neuropathy, increased age, and deep ulcers were associated with poor healing. The combination of neuropathy and ischemia was particularly associated with poor outcome of an ulcer (61% healing).

CONCLUSIONS—The Scottish foot ulcer risk score predicts both ulcer development and ulcer healing. The risk score can be a useful initial guide to determine the likelihood of poor healing. The individual criteria contributing to this overall risk are similar to other studies.

Patients with diabetes have an increased risk of lower-limb amputation, with an incidence of 50–500 per 100,000 patient-years (15). The prevalence of diabetes is increasing, and health care resources for foot problems are often inadequate. It has thus become useful to direct resources toward patients who are at the greatest risk of foot ulceration, as ulceration is the usual precursor of amputation. Various individual clinical features have been shown to predict foot ulceration (613). Such risk factors have been used collectively to determine a global risk for individual patients (1417), and some of these have been validated in routine clinical practice (16,17).

We have previously validated the foot screening tool (17), as recommended by the Scottish Intercollegiate Network Guideline (18), which uses the same simple clinical criteria as advocated by the International Working Group on the Diabetic Foot (19). In 3,526 patients followed-up prospectively for foot ulceration, those categorized initially as being at high risk of ulceration were 83 times more likely to develop a foot ulcer than those at low risk (17). Additionally, patients at low risk had a 99.7% (95% CI 99.6–99.8) chance of remaining “ulcer free” after 2.4 years follow-up. This system is now being recommended for use by the Scottish Executive (20) and is supported by software in the Scottish National web-based Diabetes Registry and information technology system (21).

We wished to assess the impact of this screening tool on the specialist diabetes foot clinic. In Dundee, the specialist diabetes foot clinic is a weekly multidisciplinary service for any patient with diabetes who has a foot ulcer in Dundee or Angus, an urban and a rural region of Tayside, Scotland. We wished to assess whether the majority of patients attending the foot clinic had previously been identified at high risk of ulceration and to see if the foot risk score was predictive of healing.

The study was approved by the Tayside Ethics Committee. All patients had diabetes as defined by the World Health Organization and were registered on the web-based Tayside Regional Diabetes Register (21). Health care professionals undertaking foot examinations, such as diabetologists, podiatrists, general practitioners, practice nurses, district nurses, and others, had participated in an education program delivered by podiatrists or doctors with an expertise in diabetes and foot care. Health care professionals had been shown how to use the foot assessment tool and how to record the information electronically on the web-based database. The details of the foot risk score are described elsewhere (17). In brief, it integrates information on previous history of foot ulceration, assessment of pulses, sensation to 10-g monofilament, presence of foot deformity, and inability to self-care (Fig. 1). The software automatically calculated the patient's individual degree of foot risk and categorized them into low, moderate, and high risk of foot ulceration. Patients underwent foot risk assessment as part of routine clinical care in hospital and general practice–based diabetes clinics within Tayside. All electronic information was shared by health care professionals using the web-based shared electronic record, which is 97% sensitive with a positive predictive value of 97% for the diagnosis of diabetes (21). Foot risk data were collected from the year 2000 onwards.

Information on patients attending the specialist foot clinic with foot ulceration was collected from 1 April 2004 until 31 December 2006. A foot ulcer was defined as a full-thickness skin break below the level of the malleoli. The following information was collected on each patient: patient age and sex, ulcer site, and the most recent foot risk score. Ulcer size was not measured. Clinical examination was performed by consultants in diabetes and vascular surgery to record absence of pulses, absence of sensation to a 10-g monofilament, presence of foot deformity, depth of ulcer using the University of Texas ulcer classification system (22), and presence of sepsis. Sepsis was defined clinically as surrounding cellulites or presence of pus. Information on outcome of ulcer and duration of ulcer from arrival at the specialist foot clinic until final outcome was recorded. Healing was defined as complete re-epithelialization of the wound. Nonhealing was defined as any patient requiring minor or major amputation, patients with a nonhealing ulcer, or a patient who died with their ulcer. A retrospective analysis was performed to determine the predictive nature of the individual clinical criteria and the overall risk score on foot ulcer healing.

Data analysis

In the data analysis, the most recent risk stratification score was used, or the risk score immediately before the onset of any ulcer. The unit of analysis was the foot ulcer. Patient demographics and details of ulcer site and outcome were compared for risk factors using χ2 tests for categorical variables, t tests for continuous data in dichotomous groups, and ANOVA for continuous data in more than two groups. Duration of ulcer had a skewed distribution and was presented by median and the interquartile range and analyzed using the Wilcoxon test. Potential predictors of a foot ulcer not healing (male sex, age, ulcer site, ulcer depth, high-risk score, absent pulses, neuropathy, foot deformity, and sepsis) were each assessed in a univariate regression analysis. Then all the variables were entered into a multivariate regression model. All analyses were carried out using SAS version 8.

Within Dundee and Angus, 7,184 patients with diabetes have had a foot risk assessment performed and recorded electronically (51.5% of all patients with diabetes). Of these, 62.9% were recorded as being at low risk, 23.9% at moderate risk, and 13.1% at high risk of developing foot ulceration. During the study period, there were 221 referrals to the specialist foot clinic for foot ulceration in 198 patients over 33 months. These were all separate episodes, and if there were simultaneous ulcers, the one that took longest to heal was included as the index ulcer. The mean age of patients was (means ± SD) 67.3 ± 12.7 years. Of these 221 ulcers, 165 (74.7%) healed, 7 (3.2%) became chronic nonhealing ulcers, 8 (3.6%) healed after minor amputation, 18 (8.1%) required major amputation, and 23 (10.4%) died with their ulcer. Further analysis was performed per referral (n = 221). If patients had multiple ulcers at referral, the ulcer that took the longest time to heal was classified as the index ulcer for further analysis. If a patient had a healed ulcer and represented with a new ulcer, they were categorized as a new ulcer event.

Of 221 referred ulcers, 97 were superficial (43.9%), 40 were deep (18.1%), and 84 were down to the bone (38.0%). In addition, 117 ulcers (52.9%) were infected, while 104 (47.1%) were not. Superficial ulcers were more likely to heal than deep ulcers or ulcers that went down to the bone (88, 68, and 63%, respectively; χ2; P < 0.001). Noninfected ulcers were more likely to heal than infected ulcers (81 vs. 69%; P = 0.02). Of all ulcers, 151 were in male subjects (68.3%) and 70 were in female subjects (31.7%). There was no difference in mean age of male (67.2 ± 11.8 years) and female (67.5 ± 14.6 years) subjects.

Of 221 ulcers, the most recent previous foot risk score was low risk in 5 subjects (2.3%), moderate risk in 52 subjects (23.5%), and high risk in 164 subjects (74.2%). Overall, 154 (69.7%) had absent foot pulses, 181 (81.9%) had absence of sensation to 10-g monofilaments, 33 (14.9%) had a foot deformity, and 88 (39.8%) had a previous foot ulcer. Of 221 ulcers, 108 (48.9%) were sited on a toe, 41 (18.6%) at a metatarsal head, 3 (1.4%) on the dorsum of the foot, 54 (24.4%) on the heel, and 15 (6.8%) elsewhere. The numbers in each risk category in the general population were 943 for high risk (13.1% of 7,184), 1,720 for moderate risk (23.9% of 7,184), and 4,521 (62.9%) for low risk. For patients in the community, the rate of attending the specialist foot clinic with a foot ulcer was 171 per 1,000 for high-risk patients (164 of 943), 30.2 per 1,000 for moderate-risk patients (52 of 1,720), and 1.1 per 1,000 for low-risk patients (5 of 4,521). The rate of referral to the specialist foot clinic with a foot ulcer for high-risk patients was 157 times higher than that of low-risk patients and 5.8 times higher than that of moderate-risk patients. Moderate-risk patients were 27 times more likely to be referred than low-risk patients.

Data on the impact of foot ulcer risk score on healing of foot ulcers is shown in Table 1. Patients at high risk of ulceration were less likely to heal than low- or moderate-risk patients (68 vs. 93%; P < 0.0001), although there was no difference in the site of ulceration for such patients (Table 1). Patients at high risk of ulceration were slightly older and took longer for their ulcers to heal (Table 1). The impact of absent foot pulses and presence of neuropathy on healing is shown in Table 2. The rate of healing for patients with absent pulses was similar to those with neuropathy (89.7 vs. 91.7%), but in patients who had both clinical criteria, the healing rate was significantly lower (61.2%; P < 0.0001). Patients with absent pulses were more likely to develop ulcers on their toes, while metatarsal head ulcers were more common in those with neuropathy (Table 2). Healing rates, ulcer sites, and time to healing were similar between those with and those without previous foot ulceration (Table 2). Although twice as many male than female subjects presented with foot ulceration, the rates of healing were similar between the sexes (Table 1). Male subjects were more likely to have toe ulcers, while female subjects were more likely to develop heel ulcers. For 33 patients with a foot deformity, 26 healed (78.8%), while in 188 patients without a foot deformity, 139 healed (73.9%; no significant difference).

For patients categorized as high risk of ulceration, absent foot pulses, neuropathy, increasing age, deep ulcer, or sepsis were all significant risk factors for a nonhealing ulcer on univariate analysis (Table 3). On multivariate analysis, absent pulses, neuropathy, increasing age, and ulcer depth remained significant.

Although the foot risk tool was developed (18) and validated (17) to predict the likelihood of foot ulceration in routine clinical practice, it appears that it is also a predictor of healing for patients who subsequently develop a foot ulcer. The healing rate was 68% in high-risk patients and 93% in low- and moderate-risk patients. The site of foot ulceration was no different between the different foot risk groups. Of five criteria comprising the risk score, only neuropathy and absent pulses were significant predictors of poor healing, showing that these were the main useful criteria within a high-risk score that predicted poor healing. Although neuropathy or absent foot pulses on their own were associated with healing rates of 93 and 88%, respectively, the combination of neuropathy and absent pulses was a good predictor of poor healing (61%). Our data show how a combination of neuropathy and ischemia predicts much poorer outcome than either criteria alone.

It was a surprise to find that having a previous foot ulcer or having a foot deformity were not predictors of poor healing. The majority of these patients had neuropathy but not vascular disease. This combination of features seems to put patients at risk of recurrent ulceration (22,23) but with ulcers that tend to heal well when managed appropriately. Although age is not part of the risk score, it was a predictor of poor ulcer healing, and nonhealing has previously been associated with age (23).

It was noticeable that 68% of referrals were male, when 53% of the diabetic population are male in Tayside. It has been shown that female subjects are more active in self-care and prevention for acute diabetes-related foot problems, while male subjects are more likely to seek help from others and take a passive approach (24). This may mean that female subjects develop fewer foot ulcers, and, when they do, they may be more likely to successfully self-manage simple ulcers. In our study, there was a nonsignificant trend toward female subjects having a higher prevalence of neuropathy, suggesting that female subjects may have more advanced diabetic foot disease when they present with foot ulceration. This may also explain why there was no sex difference in the healing rates of foot ulcers, if female subjects have more advanced disease but are better at caring for their own feet (24). Alternatively, foot ulcers in male subjects may just respond well when cared for by others.

The majority of patients referred to the specialist foot clinic with a foot ulcer had previously been identified as being at high risk of foot ulceration. Patients identified as being at high risk were 157 times more likely to attend the specialist foot clinic with an ulcer than low-risk patients. The corresponding value for moderate risk was 27 times that of increased risk. These relative risks are greater than those observed in our prospective community based follow-up of all ulcers, where which the risks were 83- and 6-fold increased, respectively (17). This may be because in the community study, many of the foot ulcers in the low-risk patients healed relatively rapidly and were not referred to the specialist foot clinic and therefore would not be included in the current analysis, which may exaggerate the relative difference in outcome between low- and high-risk patients. Of patients attending the foot clinic with a foot ulcer, 68% had already been identified as being at high risk and 98% at high or moderate risk. High-risk patients represent 12% of the diabetic population, and high-/moderate-risk patients represent 36% of them. This is reassuring that the foot risk tool is effective at identifying patients likely to ulcerate. In addition, high-risk groups of patients could be specifically targeted with preventative measures, such as education or more regular podiatry, to try and avoid future foot ulcers.

Ulcer healing rates were marginally better in this study at 75% compared with other reported series, with a healing rate of 65–67% (23,2527), even though there was a high rate of arteriopathy (70%) and the average patient age was 67 years. This may be because we followed-up our patients until there was final outcome, rather than having a defined duration of follow-up. However, in our study the amputation rate of 12% and death rate of 10% were similar to the rates reported in the literature of 8–17% amputation and 4–17% deaths (23,2527). These remain alarmingly high. We also know that patients with diabetes who undergo amputation are subsequently more likely to die and suffer further amputations than nondiabetic amputees (28). Overall, the patients seen in our specialist foot clinic are similar to those seen in other foot clinics. Predictors of an ulcer not healing were similar to previous studies. The main predictors of nonhealing appear to be ischemia (our data, 23,2931), age (our data, 23), ulcer depth (our data, 29,30,32), and ulcer size (29,33,34). Sepsis has been associated with amputation, especially in the presence of ischemia (26), and in our study was a borderline predictor of a nonhealing ulcer. This may reflect a fairly aggressive use of antibiotics. Previously, neuropathy has not been a predictor of poor healing (23,29); however, it is a predictor of reulceration (17,22,23). In the current study, neuropathy did predict poor healing, but we demonstrate that that appears to be mainly when in the presence of ischemia rather than in patients with isolated neuropathy. Previously, it has been shown that toe ulcers heal better than foot ulcers (30), but our data showed similar healing rates.

There are other standardized clinical assessment tools that both monitor ulcer progression and predict healing (22,23). These are ideal in the setting of the specialist foot clinic. However, in the community setting, where many patients are cared for by nonspecialists, the current foot risk tool could be a useful initial guide to clinicians about foot ulcer healing, without the need to understand and remember new and more complex grading schemes. It could be recommended that patients with high-risk feet who develop ulcers should be prioritized toward specialist foot clinics at an early stage because of the lower chance of healing. This may be particularly helpful in areas with restricted availability of health care resources. Once in the specialist foot clinic, the more sophisticated schemes to monitor progression and predict healing of the ulcer would be the most appropriate to use.

This study highlights the difficulties in achieving foot ulcer healing in patients with diabetes. Increasing age and distal peripheral vascular disease are particularly difficult clinical problems. We have also demonstrated that the Scottish foot ulcer risk score predicts healing of foot ulcers, as it provides an integrated assessment of arteriopathy and neuropathy. The majority of patients referred to the specialist foot clinic with an ulcer have already been identified as being at high risk, providing an opportunity for targeted educational with such patients.

Figure 1—

Foot risk stratification scheme.

Figure 1—

Foot risk stratification scheme.

Close modal
Table 1—

Patient criteria and outcomes of foot ulcer in patients presenting to the specialist foot clinic for male and female patients according to SCI-DC clinical risk score (17) of foot ulceration

MaleFemaleP valueLow and moderate riskHigh riskP valueAll patients
n 151 70  57 164  221 
Sex (male) — — — 44 (77.2) 107 (65.2) NS 151 (68.3) 
Age (years) 67.2 ± 11.79 67.5 ± 14.56 NS 62.7 ± 13.76 68.9 ± 11.96 0.001 67.3 ± 12.70 
No foot pulses 106 (70.2) 48 (68.6) NS — — — 154 (69.7) 
Sensation to 10-g monofilament 119 (78.8) 62 (88.6) NS — — — 181 (81.9) 
Foot deformity 21 (13.9) 12 (17.1) NS — — — 33 (14.9) 
Duration of ulcer (months) 3 (2–6) 2 (2–4) NS 2 (2–4) 3 (2–6) 0.04 3 (2–5) 
Ulcer site        
    Toe 83 (55.0) 25 (35.7)  31 (54.4) 77 (47.0)  108 (48.9) 
    Metatarsal head 28 (18.5) 13 (18.6)  9 (15.8) 32 (19.5)  41 (18.6) 
    Dorsum 2 (1.3) 1 (1.4)  1 (1.8) 2 (1.3)  3 (1.4) 
    Heel 29 (19.2) 25 (35.7)  13 (22.8) 41 (25.0)  54 (24.4) 
    Other 9 (6.0) 6 (8.6) 0.05 3 (5.3) 12 (7.3) NS 15 (6.8) 
Ulcer depth        
    Superficial 60 (39.7) 37 (52.9)  31 (54.4) 66 (40.2)  97 (43.9) 
    Deep 25 (16.6) 15 (21.4)  10 (17.5) 30 (18.3)  40 (18.1) 
    Bone 66 (43.7) 18 (25.7) 0.04 16 (28.1) 68 (41.5) NS 84 (38.0) 
Sepsis 86 (56.9) 31 (44.3) 0.07 28 (49.1) 89 (54.3) NS 117 (52.9) 
Outcome        
    Healed 115 (76.2) 50 (71.4)  53 (93.0) 112 (68.3)  165 (74.7) 
    Chronic ulcer 2 (1.3) 5 (7.1)  0 (0) 7 (4.3)  7 (3.2) 
    Minor amputation 7 (4.6) 1 (1.4)  1 (1.9) 7 (4.3)  8 (3.6) 
    Major amputation 12 (7.9) 6 (8.6)  1 (1.9) 17 (10.4)  18 (8.1) 
    Died 15 (9.9) 8 (11.4) NS 2 (3.8) 21 (12.8) 0.0001 23 (10.4) 
MaleFemaleP valueLow and moderate riskHigh riskP valueAll patients
n 151 70  57 164  221 
Sex (male) — — — 44 (77.2) 107 (65.2) NS 151 (68.3) 
Age (years) 67.2 ± 11.79 67.5 ± 14.56 NS 62.7 ± 13.76 68.9 ± 11.96 0.001 67.3 ± 12.70 
No foot pulses 106 (70.2) 48 (68.6) NS — — — 154 (69.7) 
Sensation to 10-g monofilament 119 (78.8) 62 (88.6) NS — — — 181 (81.9) 
Foot deformity 21 (13.9) 12 (17.1) NS — — — 33 (14.9) 
Duration of ulcer (months) 3 (2–6) 2 (2–4) NS 2 (2–4) 3 (2–6) 0.04 3 (2–5) 
Ulcer site        
    Toe 83 (55.0) 25 (35.7)  31 (54.4) 77 (47.0)  108 (48.9) 
    Metatarsal head 28 (18.5) 13 (18.6)  9 (15.8) 32 (19.5)  41 (18.6) 
    Dorsum 2 (1.3) 1 (1.4)  1 (1.8) 2 (1.3)  3 (1.4) 
    Heel 29 (19.2) 25 (35.7)  13 (22.8) 41 (25.0)  54 (24.4) 
    Other 9 (6.0) 6 (8.6) 0.05 3 (5.3) 12 (7.3) NS 15 (6.8) 
Ulcer depth        
    Superficial 60 (39.7) 37 (52.9)  31 (54.4) 66 (40.2)  97 (43.9) 
    Deep 25 (16.6) 15 (21.4)  10 (17.5) 30 (18.3)  40 (18.1) 
    Bone 66 (43.7) 18 (25.7) 0.04 16 (28.1) 68 (41.5) NS 84 (38.0) 
Sepsis 86 (56.9) 31 (44.3) 0.07 28 (49.1) 89 (54.3) NS 117 (52.9) 
Outcome        
    Healed 115 (76.2) 50 (71.4)  53 (93.0) 112 (68.3)  165 (74.7) 
    Chronic ulcer 2 (1.3) 5 (7.1)  0 (0) 7 (4.3)  7 (3.2) 
    Minor amputation 7 (4.6) 1 (1.4)  1 (1.9) 7 (4.3)  8 (3.6) 
    Major amputation 12 (7.9) 6 (8.6)  1 (1.9) 17 (10.4)  18 (8.1) 
    Died 15 (9.9) 8 (11.4) NS 2 (3.8) 21 (12.8) 0.0001 23 (10.4) 

Data are means ± SD, n (%), or median (interquartile range). NS, nonsignificant

Table 2—

Patient criteria and outcomes of foot ulcer in patients presenting to the specialist foot clinic

No foot pulses (no neuropathy)NeuropathyNo pulse and neuropathyP valueNo previous foot ulcerPrevious foot ulcerP value
n 33 67 121  133 88  
Sex (male) 26 (78.8) 39 (65.0) 80 (66.1) NS 91 (68.4) 60 (68.2) NS 
Age (years) 73.5 ± 7.52 58.05 ± 14.36 71.06 ± 9.71 <0.0001 66.61 ± 12.80 68.54 ± 12.39 NS 
Ulcer duration 2 (1–4) 2 (2–4) 3 (2–7) 0.02 3 (2–5) 3 (2–6) NS 
Ulcer site        
    Toe 22 (66.7) 25 (41.7) 58 (47.9)  68 (51.1) 40 (45.5)  
    Metatarsal head 2 (6.1) 19 (31.7) 16 (13.2)  21 (15.8) 20 (22.7)  
    Dorsum 0 (0) 2 (3.3) 1 (0.8)  2 (1.5) 1 (1.1)  
    Heel 8 (24.2) 10 (16.7) 36 (29.8)  34 (25.6) 20 (22.7)  
    Other 1 (3.0) 4 (6.7) 10 (8.3) 0.01 8 (6.0) 7 (8.8) NS 
Ulcer depth        
    Superficial 14 (42.4) 32 (55.3) 47 (38.8)  66 (49.6) 31 (35.6)  
    Deep 6 (18.2) 10 (16.7) 23 (19.0)  22 (16.5) 18 (20.7)  
    Bone 13 (39.4) 18 (30.0) 51 (42.2) NS 45 (33.8) 38 (43.7) NS 
Sepsis 17 (51.5) 29 (48.3) 68 (56.2) NS 69 (51.9) 47 (54.0) NS 
Outcome        
    Healed 29 (87.9) 62 (92.5) 74 (61.2)  103 (77.4) 62 (70.4)  
    Chronic ulcer 0 (0) 0 (0) 7 (5.8)  4 (3.0) 3 (3.4)  
    Minor amputation 0 (0) 1 (1.5) 7 (5.8)  4 (3.0) 4 (4.5)  
    Major amputation 2 (6.1) 2 (3.0) 14 (11.6)  9 (6.8) 9 (10.2)  
    Died 2 (6.1) 2 (3.0) 19 (15.7) <0.0001 13 (9.8) 10 (11.4) NS 
No foot pulses (no neuropathy)NeuropathyNo pulse and neuropathyP valueNo previous foot ulcerPrevious foot ulcerP value
n 33 67 121  133 88  
Sex (male) 26 (78.8) 39 (65.0) 80 (66.1) NS 91 (68.4) 60 (68.2) NS 
Age (years) 73.5 ± 7.52 58.05 ± 14.36 71.06 ± 9.71 <0.0001 66.61 ± 12.80 68.54 ± 12.39 NS 
Ulcer duration 2 (1–4) 2 (2–4) 3 (2–7) 0.02 3 (2–5) 3 (2–6) NS 
Ulcer site        
    Toe 22 (66.7) 25 (41.7) 58 (47.9)  68 (51.1) 40 (45.5)  
    Metatarsal head 2 (6.1) 19 (31.7) 16 (13.2)  21 (15.8) 20 (22.7)  
    Dorsum 0 (0) 2 (3.3) 1 (0.8)  2 (1.5) 1 (1.1)  
    Heel 8 (24.2) 10 (16.7) 36 (29.8)  34 (25.6) 20 (22.7)  
    Other 1 (3.0) 4 (6.7) 10 (8.3) 0.01 8 (6.0) 7 (8.8) NS 
Ulcer depth        
    Superficial 14 (42.4) 32 (55.3) 47 (38.8)  66 (49.6) 31 (35.6)  
    Deep 6 (18.2) 10 (16.7) 23 (19.0)  22 (16.5) 18 (20.7)  
    Bone 13 (39.4) 18 (30.0) 51 (42.2) NS 45 (33.8) 38 (43.7) NS 
Sepsis 17 (51.5) 29 (48.3) 68 (56.2) NS 69 (51.9) 47 (54.0) NS 
Outcome        
    Healed 29 (87.9) 62 (92.5) 74 (61.2)  103 (77.4) 62 (70.4)  
    Chronic ulcer 0 (0) 0 (0) 7 (5.8)  4 (3.0) 3 (3.4)  
    Minor amputation 0 (0) 1 (1.5) 7 (5.8)  4 (3.0) 4 (4.5)  
    Major amputation 2 (6.1) 2 (3.0) 14 (11.6)  9 (6.8) 9 (10.2)  
    Died 2 (6.1) 2 (3.0) 19 (15.7) <0.0001 13 (9.8) 10 (11.4) NS 

Data are means ± SD, n (%), median (interquartile range). Data analyzed according to absent pulses and neuropathy as well as history of previous foot ulcer. NS, nonsignificant.

Table 3—

Univariate and multivariate regression analysis of variables potentially predictive of foot ulcer not healing

Univariate analysisMultivariate analysis
Male sex 0.78 (0.413–1.484) NS 0.67 (0.313–1.446) NS 
Age (plus 1 year) 1.05 (1.023–1.085) 0.0006 1.04 (1.002–1.078) 0.04 
Ulcer site   
    Meta head versus toe 0.88 (0.375–2.098) NS 1.59 (0.562–4.515) NS 
    Dorsum versus toe 1.58 (0.137–18.106) NS 8.53 (0.234–310.77) NS 
    Heel versus toe 1.45 (0.702–2.990 ) NS 1.56 (0.668–3.646) NS 
    Other versus toe 0.79 (0.207–3.011) NS 1.14 (0.241–5.445) NS 
Ulcer depth   
    Deep versus superficial 3.41 (1.392–8.356) 0.007 2.93 (1.081–7.935) 0.03 
    Bone versus superficial 4.14 (1.958–8.766) 0.0002 4.87 (1.846–12.842) 0.001 
    High risk 6.16 (2.114–17.902) 0.0009 — 
    Absent pulses 6.14 (2.325–16.213) 0.0002 4.78 (1.570–14.531) 0.006 
    Neuropathy 3.63 (1.229–10.698) 0.02 4.98 (1.556–15.953) 0.006 
    Previous ulcer 1.46 (0.793–2.702) NS 1.11 (0.546–2.235) NS 
    Foot deformity 0.76 (0.312–1.871) NS 0.68 (0.237–1.974) NS 
    Sepsis 1.87 (0.998–3.491) 0.051 1.14 (0.503–2.600) NS 
Univariate analysisMultivariate analysis
Male sex 0.78 (0.413–1.484) NS 0.67 (0.313–1.446) NS 
Age (plus 1 year) 1.05 (1.023–1.085) 0.0006 1.04 (1.002–1.078) 0.04 
Ulcer site   
    Meta head versus toe 0.88 (0.375–2.098) NS 1.59 (0.562–4.515) NS 
    Dorsum versus toe 1.58 (0.137–18.106) NS 8.53 (0.234–310.77) NS 
    Heel versus toe 1.45 (0.702–2.990 ) NS 1.56 (0.668–3.646) NS 
    Other versus toe 0.79 (0.207–3.011) NS 1.14 (0.241–5.445) NS 
Ulcer depth   
    Deep versus superficial 3.41 (1.392–8.356) 0.007 2.93 (1.081–7.935) 0.03 
    Bone versus superficial 4.14 (1.958–8.766) 0.0002 4.87 (1.846–12.842) 0.001 
    High risk 6.16 (2.114–17.902) 0.0009 — 
    Absent pulses 6.14 (2.325–16.213) 0.0002 4.78 (1.570–14.531) 0.006 
    Neuropathy 3.63 (1.229–10.698) 0.02 4.98 (1.556–15.953) 0.006 
    Previous ulcer 1.46 (0.793–2.702) NS 1.11 (0.546–2.235) NS 
    Foot deformity 0.76 (0.312–1.871) NS 0.68 (0.237–1.974) NS 
    Sepsis 1.87 (0.998–3.491) 0.051 1.14 (0.503–2.600) NS 

Data are odds ratio (95% CI) P value. High risk not included in multivariate analysis as it is comprised of other component criteria. NS, nonsignificant.

We thank all the clinical staff who performed clinical assessments.

1.
Morris AD, McAlpine R, Steinke D, Boyle DI, Ebrahim AR, Vasudev N, Stewart CP, Jung RT, Leese GP, MacDonald TM, Newton RW: Diabetes and lower limb amputation in the community: a retrospective cohort study. DARTS/MEMO collaboration.
Diabetes Care
21
:
738
–743,
1998
2.
van Houtum WH, Rauwerda JA, Ruwaard D, Schaper NC, Bakker K: Reduction in diabetes-related lower-extremity amputations in the Netherlands: 1991–2000.
Diabetes Care
27
:
1042
–1046,
2004
3.
Calle-Pascual AL, Redondo MJ, Ballesteros M, Martinez-Salinas MA, Diaz JA, De Matias P, Calle JR, Gil E, Jimenez M, Serrano FJ, Martin-Alvarez PJ, Maranes JP: Nontraumatic lower extremity amputations in diabetic and non-diabetic subjects in Madrid, Spain.
Diabetes Metab
23
:
519
–523,
1997
4.
Witso E, Ronningen H: Lower limb amputations: registration of all lower limb amputations performed at the University Hospital of Trondheim, Norway, 1994–1997.
Prosthet Orthot Int
25
:
181
–185,
2001
5.
Van Houtum WH, Lavery LA: Outcomes associated with diabetes-related amputations in the Netherlands and in the state of California, USA.
J Intern Med
240
:
227
–231,
1996
6.
Armstrong DG, Lavery LA, Vela SA, Quebedeaux TL, Fleischli JG: Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration.
Arch Int Med
158
:
289
–292,
1998
7.
Veves A, Murray HJ, Young MJ, Boulton AJ: The risk of foot ulceration in diabetic patients with high foot pressure: a prospective study.
Diabetologia
35
:
660
–663,
1992
8.
Lavery LA, Armstrong DG, Vela SA, Quebedeaux TL, Fleischli JG: Practical criteria for screening patients at high risk for diabetic foot ulceration.
Arch Int Med
26
:
157
–162,
1998
9.
Young MJ, Breddy JL, Veves A, Boulton MJ: The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds: a prospective study.
Diabetes Care
17
:
557
–560,
1994
10.
Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ: Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration.
Diabetes Care
21
:
1071
–1075,
1998
11.
Rith-Najarian SJ, Stolusky T, Gohdes DM: Identifying diabetic patients at high risk for lower extremity amputation in a primary care health care setting: a prospective evaluation of simple screening criteria.
Diabetes Care
15
:
1386
–1389,
1992
12.
Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A: Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial.
Diabetes Care
23
:
606
–611,
2000
13.
Boyko EJ, Ahoroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG: A prospective study of risk factors for diabetic foot ulcer: the Seattle Diabetic Foot Study.
Diabetes Care
22
:
1036
–1042,
1999
14.
Peters EJ, Lavery LA: Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot.
Diabetes Care
24
:
1442
–1447,
2001
15.
Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ER, Whalley AM, Widdows P, Williamson S, Boulton AJ: The North West Diabetes Care Foot Study: incidence of, risk factors for, new diabetic foot ulceration in a community-based cohort.
Diabet Med
19
:
377
–384,
2002
16.
Boyko EJ, Ahoroni JH, Cohen V, Nelson KM, Heagerty PJ: Prediction of diabetic foot ulcer occurrence using commonly available clinical information.
Diabetes Care
29
:
1202
–1207,
2006
17.
Leese GP, Reid F, Green V, McAlpine R, Cunningham S, Emslie-Smith A, Morris AD, McMurray B, Connacher A: Predicting foot ulceration in diabetes: validation of a clinical tool in a population-based study.
Int J Clin Prac
60
:
541
–545,
2006
18.
Scottish Intercollegiate Guideline Network (SIGN): SIGN guideline 55: the management of diabetes: Royal College of Physicians Edinburgh: SIGN, [article online],
2001
. Available at www.sign.ac.uk/guidelines/index.html. Accessed 12 June 2007
19.
International Diabetes Federation: International concensus on the diabetic foot: five cornerstones, identification of the foot at risk: consensus meeting [article online],
2003
. Available at www.iwgdf.org/concensus. Accessed 12 June 2007
20.
Diabetes Action Plan: Scottish Executive, Edinburgh [article online],
2006
. Available at www.scotland.gov.uk. Accessed 12 June 2007
21.
Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, MacDonald TM: The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register.
Br Med J
315
:
524
–528,
1997
22.
Armstrong DG, Lavery LA, Harkless LB: Validation of a diabetic wound classification system: the contribution of depth, infection, and ischemia to risk of amputation.
Diabetes Care
21
:
855
–859,
1998
23.
Pound N, Chipchase S, Treece K, Game F, Jeffcoate W: Ulcer free survival following management of foot ulcers in diabetes.
Diabet Med
22
:
1306
–1309,
2005
24.
Hjelm K, Nyberg P, Apelqvist J: Gender influences beliefs about health and illness in diabetic subjects with severe foot lesions.
J Adv Nurs
40
:
673
–684,
2002
25.
Apleqvist J: Wound healing in diabetes: outcomes and costs.
Clin Podiat Med Surg
15
:
21
–39,
1998
26.
Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJM: A comparison of two diabetic foot ulcer classification systems.
Diabetes Care
24
:
84
–88,
2001
27.
Jeffcoate WJ, Chipchase SY, Ince P, Game FL: Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures.
Diabetes Care
29
:
1784
–1787,
2006
28.
Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP: Mortality and hospitalisation in patients after amputation: a comparison between patients with and without diabetes.
Diabetes Care
29
:
2252
–2256,
2006
29.
Treece KA, Macfarlane RM, Pound N, Game FL, Jeffcoate WJ: Validation of a system of foot ulcer classification in diabetes mellitus.
Diabet Med
21
:
987
–991,
2004
30.
Beckert S, Witte M, Wicke C, Konigsrainer A, Coerper S: A new wound-based severity score for diabetic foot ulcers: a prospective analysis of 1,000 patients.
Diabetes Care
29
:
988
–992,
2006
31.
Adler AI, Boyko EJ, Ahroni JH, Smith DG: Lower-extremity amputation in diabetes: the independent effects of peripheral vascular disease, sensory neuropathy and foot ulcers.
Diabetes Care
22
:
1029
–1035,
1999
32.
Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA: Diabetic neuropathic foot ulcers and amputation.
Wound Repair Regen
13
:
230
–236,
2005
33.
Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Armstrong DG, Harkless LB, Boulton AJM: The effects of ulcer size and site, patients age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers.
Diabet Med
18
:
133
–138,
2001
34.
Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA: Diabetic neuropathic foot ulcers: predicting which ones will not heal.
Am J Med
115
:
627
–631,
2003

Published ahead of print at http://care.diabetesjournals.org on 22 May 2007. DOI: 10.2337/dc07-0553.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.